학술논문

IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
Document Type
Article
Source
Leukemia (08876924). Jul2006, Vol. 20 Issue 7, p1231-1237. 7p.
Subject
*LEUKEMIA diagnosis
*CANCER diagnosis
*IMMUNOGLOBULIN genes
*LYMPHOCYTIC leukemia
*CELLS
Language
ISSN
0887-6924
Abstract
B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis. To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases with de novo B-PLL. Immunoglobulin heavy chain genes analysis showed an unmutated pattern (>98% homology to germ line) in 9/17 cases (53%), with 100% homology in eight. In the remaining, it ranged from 90 to 97.4%, with three cases slightly mutated (98–95%) and five heavily mutated (<95%). All B-PLL utilized members of VH3 (11/17) and VH4 (6/17) families, with V3-23, V4-59 and V4-34 gene accounting for more than half of them, regardless of mutational status. ZAP-70, assessed by flow cytometry, ranged from 1 to 91% cells, being 20% in 57% of cases. CD38 ranged from 1 to 99% (median 21%). There was no correlation between IgVH status and ZAP-70 or CD38 expression, but male gender and del(17p) were more common in the unmutated group. Neither IgVH mutations, CD38 expression nor del(17p) influenced patients’ outcome. Unexpectedly, ZAP-70+ B-PLL patients survived longer (40 months) than ZAP-70− B-PLL (8 months). B-PLL appears biologically heterogeneous regarding IgVH mutations, ZAP-70 and CD38 expression, showing a pattern distinct from that of other lymphoproliferative disorders.Leukemia (2006) 20, 1231–1237. doi:10.1038/sj.leu.2404238; published online 27 April 2006 [ABSTRACT FROM AUTHOR]